Focus:
Cardiovascular
-
27 September 2019 Analysis
Using a quadruple polypill to prevent major CV events
Although CV disease is the main cause of death globally, it is a particularly significant issue in developing countries where there are more challenges to accessing medication. One solution to...
-
17 September 2019 Comment
Smoke and mirrors: The complicated truth about vaping
There are at least 215 possible cases across 25 states where the development of severe lung disease has been linked to vaping.
-
13 September 2019 News
Penn researchers study cancer therapy in heart disease treatment
A research team from Penn Medicine at the University of Pennsylvania has been studying CAR T-cell therapy, which is used to fight cancer, in the treatment of heart disease.
-
6 September 2019 Comment
ESC updates first-line treatment guidelines for type 2 diabetics with cardiovascular disease
The ESC’s updated guidelines are an important step forward in addressing CV risk, which has historically remained an unresolved issue in patients living with diabetes.
-
6 September 2019 whitepapers
Case Study: Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.
-
4 September 2019 Analysis
Examining AstraZeneca’s Farxiga: more than a diabetes drug
At the 2019 ESC congress in Paris, AstraZeneca presented full results from the Phase III DAPA-HF trial studying type 2 diabetes drug Farxiga in HFrEF. The drug showed great promise...
-
2 September 2019 News
Novartis’s heart failure drug Entresto presents mixed trial results
Novartis has announced that its heart failure with reduced ejection fraction (HFrEF) drug Entresto (sacubitril/valsartan) has shown further efficacy in two Phase IV trials, PROVE-HF and EVALUATE-HF.
-
22 August 2019 Comment
FDA calls surprise AdCom meeting on Vascepa: what does this mean for its upcoming label expansion?
GlobalData believes a decision for an AdCom to be held does not translate negatively to the drug’s chances for a successful FDA label expansion.
-
20 August 2019 News
AstraZeneca’s diabetes drug Farxiga performs well in heart failure patients
AstraZeneca has announced that Farxiga (dapagliflozin) met its primary endpoint in heart failure-focused Phase III DAPA-HF trial of patients with reduced ejection fraction (HFrEF).
-
19 August 2019 News
Researchers develop compound to reduce injury due to heart attacks
Researchers from Virginia Tech University (VT) have developed a variant of the compound alphaCT1, which can improve heart attack recovery if administered during, or soon after, a heart attack.